Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery, according to a recent study published in Nature Medicine.
Direct-to-consumer platforms for testosterone therapy don’t always provide care in concordance with professional guidelines, according to a recent Northwestern Medicine study.
An epigenetics drug currently being used for the treatment of blood cancers and rare sarcomas can stop the growth of bladder cancer by activating the immune system, according to a new study.
Northwestern Medicine investigators have identified a gene that confers resistance to a common prostate cancer treatment, according to a study published in Cancer Research.
From teasing out determinants of health disparities to developing precision medicine treatments, clinicians and scientists from the Lurie Cancer Center are dramatically changing the landscape for all men with prostate cancer.
Two Northwestern Medicine studies are improving the understanding of epigenetic mechanisms in cancer development and progression, and identifying novel cancer driver genes that may help identify patients who will benefit from immunotherapy.
Northwestern Medicine investigators have discovered that oncogenes contain specific epigenetic markers called broad genic repression domains, which could help identify potential therapeutic targets for cancer treatment.
Maxwell Edmonds, a third-year medical student in the Medical Scientist Training Program (MSTP), recently defended his doctoral thesis on generating testicular organoids and looks back on his Feinberg journey so far.
A new study found that Black men with metastatic prostate cancer were more likely to have tumor mutations than white or Asian men, highlighting the significance genetic drivers have in increasing one’s risk for developing aggressive prostate cancer.
Inhibiting an epigenetic regulator called DOT1L could be a key to slowing treatment-resistant prostate cancer, according to a recent Northwestern Medicine study.